CC-90001 clinical trials
Also written CC-90001.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses CC-90001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Celgene (7) · Celgene Corporation (2) · Bristol-Myers Squibb (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses CC-90001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT05625412Written as BMS-986360
- A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary FibrosisTerminatedPhase 2CelgeneNCT03142191Written as CC-90001
- Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisTerminatedPhase 2CelgeneNCT04048876Written as CC-90001
- Metabolism and Excretion of [14C]CC-90001 in Healthy Male SubjectsCompletedPhase 1CelgeneNCT04655898Written as [14C]CC-90001
- A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy SubjectsCompletedPhase 1CelgeneNCT03742882Written as CC-90001
- A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy SubjectsCompletedPhase 1CelgeneNCT03958864Written as CC-90001
- A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult SubjectsCompletedPhase 1CelgeneNCT03363815Written as CC-90001
- Safety and PK Study of CC-90001 in Subjects With Pulmonary FibrosisCompletedPhase 1CelgeneNCT02510937Written as CC-90001
- Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect StudyCompletedPhase 1Celgene CorporationNCT02321644Written as CC-90001
- First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001CompletedPhase 1Celgene CorporationNCT02110420Written as CC-90001
Codes
What other systems call CC-90001 · ClinicalTrials.gg INT001834
- MeSH (NLM) C000722276CC-90001One source NLM
- UNII (FDA) JD5ZWE631KCC-90001Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722276 | CC-90001 | One source NLM |
| UNII (FDA) | JD5ZWE631K | CC-90001 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.